Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Endometrial Neoplasms × durvalumab × Clear all

Phase

Phase 2 4 Phase 3 2 Phase 1 2 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 2 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Recurrent Squamous Cell Lung Carcinoma 1 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Gallbladder Neoplasms 1 Endometrial Neoplasms 1 Carcinoma 1 Biliary Tract Neoplasms 1

Interventions

Paclitaxel 3 Megestrol Acetate 3 Carboplatin 3 Medroxyprogesterone Acetate 2 Cisplatin 2 spartalizumab 1 sintilimab 1 olaparib 1 niraparib 1 navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1 durvalumab 1 Tablets 1 Progestins 1 Observation 1 Letrozole 1 Gonadotropin-Releasing Hormone 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05255653 2024-11-29

RAINBO

Leiden University Medical Center

Phase 2/3 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡